Expression of angiogenic growth factors VEGF, bFGF and ANG1 in colon cancer after bevacizumab treatment in vitro: A potential self-regulating mechanism

Zhao,Minjian; Yu, Zhaoshi; Li,Zhihong; Tang,Jun; Lai,Xu; Liu,Liming

doi:10.3892/or.2016.5231

Expression of angiogenic growth factors VEGF, bFGF and ANG1 in colon cancer after bevacizumab treatment in vitro: A potential self-regulating mechanism

Authors:
- Minjian Zhao
- Zhaoshi Yu
- Zhihong Li
- Jun Tang
- Xu Lai
- Liming Liu
View Affiliations

Affiliations: Department of General Surgery, Central Hospital of Ezhou, Hubei 436000, P.R. China
Published online on: November 8, 2016 https://doi.org/10.3892/or.2016.5231
Pages: 601-607

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to examine changes in the expression of angiogenic growth factors in vascular endothelial cells isolated from colon cancer after bevacizumab treatment in vitro, and to explore a potential mechanism of their self-regulation as a possible mechanism for antiangiogenic therapy failure in clinics. Vascular endothelial cells were isolated from tumors of colon cancer patients and transfected with recombinant adeno-associated virus type 2-vascular endothelial growth factor (VEGF) or pGIPZ-VEGF RNA interference in order to upregulate or downregulate VEGF expression. Changes in VEGF expression and its correlation with the expression of angiogenesis-related factors, including basic fibroblast growth factor (bFGF) and angiopoietin 1 (ANG1), after treatment with bevacizumab in vitro, were investigated. The results showed that in cells with VEGF overexpression, bFGF and ANG1 were downregulated, whereas in cells in which VEGF was knocked down, upregulation of bFGF and ANG1 was detected. In cells treated with bevacizumab, a significant upregulation of VEGF and downregulation of bFGF and ANG1 were observed. Our data indicate that after bevacizumab treatment, a potential self-regulating mechanism of angiogenic growth factors in colon cancer-derived endothelial cells is activated, which may explain why current antiangiogenic therapy with bevacizumab has limited effects in prolonging the survival of colon cancer patients.

View Figures

View References

1	Muzny DM, Bainbridge MN, Chang K, Dinh HH, Drummond JA, Fowler G, Kovar CL, Lewis LR, Morgan MB, Newsham IF, et al: Cancer Genome Atlas Network: Comprehensive molecular characterization of human colon and rectal cancer. Nature. 487:330–337. 2012. View Article : Google Scholar : PubMed/NCBI
2	Yadav L, Puri N, Rastogi V, Satpute P and Sharma V: Tumour Angiogenesis and Angiogenic Inhibitors: A Review. J Clin Diagn Res. 9:XE01–XE05. 2015.PubMed/NCBI
3	Papadimitriou K, Rolfo C, Dewaele E, Van De Wiel M, Van den Brande J, Altintas S, Huizing M, Specenier P and Peeters M: Incorporating anti-VEGF pathway therapy as a continuum of care in metastatic colorectal cancer. Curr Treat Options Oncol. 16:182015. View Article : Google Scholar : PubMed/NCBI
4	Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 350:2335–2342. 2004. View Article : Google Scholar : PubMed/NCBI
5	Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, et al: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol. 26:2013–2019. 2008. View Article : Google Scholar : PubMed/NCBI
6	Tebbutt NC, Wilson K, Gebski VJ, Cummins MM, Zannino D, van Hazel GA, Robinson B, Broad A, Ganju V, Ackland SP, et al: Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol. 28:3191–3198. 2010. View Article : Google Scholar : PubMed/NCBI
7	Grothey A and Ellis LM: Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies. Cancer J. 14:170–177. 2008. View Article : Google Scholar : PubMed/NCBI
8	Shibuya M: Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis. BMB Rep. 41:278–286. 2008. View Article : Google Scholar : PubMed/NCBI
9	Fleck BW and McIntosh N: Pathogenesis of retinopathy of prematurity and possible preventive strategies. Early Hum Dev. 84:83–88. 2008. View Article : Google Scholar : PubMed/NCBI
10	Heidary G, Vanderveen D and Smith LE: Retinopathy of prematurity: Current concepts in molecular pathogenesis. Semin Ophthalmol. 24:77–81. 2009. View Article : Google Scholar : PubMed/NCBI
11	Karamysheva AF: Mechanisms of angiogenesis. Biochemistry. 73:751–762. 2008.PubMed/NCBI
12	Kitano H: Cancer as a robust system: Implications for anticancer therapy. Nat Rev Cancer. 4:227–235. 2004. View Article : Google Scholar : PubMed/NCBI
13	Schrattenholz A and Soskić V: What does systems biology mean for drug development? Curr Med Chem. 15:1520–1528. 2008. View Article : Google Scholar : PubMed/NCBI
14	Li B, Li GG, Xiang Y and Xu LJ: VEGF affects the expression of TGF-β in retinal neovascularization: A preliminary study about redundancy of growth factor. Int J Ophthalmol. 8:2391–2393. 2008.
15	Gacche RN and Meshram RJ: Angiogenic factors as potential drug target: Efficacy and limitations of anti-angiogenic therapy. Biochim Biophys Acta. 1846:161–179. 2014.PubMed/NCBI
16	Kerbel RS: Tumor angiogenesis. N Engl J Med. 358:2039–2049. 2008. View Article : Google Scholar : PubMed/NCBI
17	Giampieri R, Scartozzi M, Del Prete M, Fulli A, Faloppi L, Bianconi M, Maccaroni E and Cascinu S: The ‘angiogenetic ladder’, step-wise angiogenesis inhibition in metastatic colorectal cancer. Cancer Treat Rev. 40:934–941. 2014. View Article : Google Scholar : PubMed/NCBI
18	Hanahan D and Weinberg RA: The hallmarks of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
19	Mahadevan R and Lovley DR: The degree of redundancy in metabolic genes is linked to mode of metabolism. Biophys J. 94:1216–1220. 2008. View Article : Google Scholar : PubMed/NCBI
20	Krakauer DC and Plotkin JB: Redundancy, antiredundancy, and the robustness of genomes. Proc Natl Acad Sci USA. 99:1405–1409. 2002. View Article : Google Scholar : PubMed/NCBI
21	Louis EJ: Evolutionary genetics: Making the most of redundancy. Nature. 449:673–674. 2007. View Article : Google Scholar : PubMed/NCBI
22	Saharinen P, Eklund L, Miettinen J, Wirkkala R, Anisimov A, Winderlich M, Nottebaum A, Vestweber D, Deutsch U, Koh GY, et al: Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell-cell and cell-matrix contacts. Nat Cell Biol. 10:527–537. 2008. View Article : Google Scholar : PubMed/NCBI
23	Cao Y and Liu Q: Therapeutic targets of multiple angiogenic factors for the treatment of cancer and metastasis. Adv Cancer Res. 97:203–224. 2007. View Article : Google Scholar : PubMed/NCBI
24	Wong ET and Brem S: Antiangiogenesis treatment for glioblastoma multiforme: Challenges and opportunities. J Natl Compr Canc Netw. 6:515–522. 2008.PubMed/NCBI
25	Moens S, Goveia J, Stapor PC, Cantelmo AR and Carmeliet P: The multifaceted activity of VEGF in angiogenesis - Implications for therapy responses. Cytokine Growth Factor Rev. 25:473–482. 2014. View Article : Google Scholar : PubMed/NCBI
26	Tabernero J: The role of VEGF and EGFR inhibition: Implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res. 5:203–220. 2007. View Article : Google Scholar : PubMed/NCBI
27	Chung YC, Hou YC, Chang CN and Hseu TH: Expression and prognostic significance of angiopoietin in colorectal carcinoma. J Surg Oncol. 94:631–638. 2006. View Article : Google Scholar : PubMed/NCBI
28	Lieu C, Heymach J, Overman M, Tran H and Kopetz S: Beyond VEGF: Inhibition of the fibroblast growth factor pathway and antiangiogenesis. Clin Cancer Res. 17:6130–6139. 2011. View Article : Google Scholar : PubMed/NCBI
29	Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ and Holash J: Vascular-specific growth factors and blood vessel formation. Nature. 407:242–248. 2000. View Article : Google Scholar : PubMed/NCBI
30	Dvorak HF: Discovery of vascular permeability factor (VPF). Exp Cell Res. 312:522–526. 2006. View Article : Google Scholar : PubMed/NCBI
31	Folkman J: Angiogenesis: An organizing principle for drug discovery? Nat Rev Drug Discov. 6:273–286. 2007. View Article : Google Scholar : PubMed/NCBI